This article was originally published in The Gray Sheet
Myriad predictive medicine products, including the BracAnalysis test for assessing a woman's risk of developing breast or ovarian cancer, will be distributed by LabCorp's 600-rep U.S. sales force in addition to Myriad's 85-person oncology sales force, under an exclusive marketing alliance announced Dec. 4...
You may also be interested in...
Myriad Genetics will concentrate direct-to-consumer advertising in Atlanta and Denver for its BRACAnalysis breast and ovarian cancer genetic predisposition testing service as the firm moves beyond physician education as a sole means of promotion
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.